莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折

路透中文08-01 02:27

BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折

7月31日 - ** 疫苗制造商莫德纳（Moderna） MRNA.O 的股价下跌约4%，至55.71美元

** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (link)

** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节

** 多伦多道明 Cowen 分析师泰勒·范·布伦（Tyler Van Buren）表示，这一进展“略显令人失望”，因为诺如病毒曾是除新冠、呼吸道合胞病毒（RSV）和流感之外，晚期传染病领域中前景较为明朗的机遇之一

** 他表示，这一挫折使该项目从潜在的2026年催化剂转向了更不确定的研发路径，同时也可能对更广泛的mRNA平台生产力讨论产生一定程度的负面影响

** 公司报告第二季度营收为1.45亿美元，超过分析师预估的1.03亿美元——数据由LSEG汇编

** 计入盘中波动，该股今年以来累计涨幅约为90%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656956093?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-01 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656956093","market":"hk","top_or_hot":-1,"title":"莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折</title></head><body><p><span>7月31日</span><span> - </span>** 疫苗制造商莫德纳（<a href=\"https://laohu8.com/S/MRNA\">Moderna</a>） <span>MRNA.O</span> 的股价下跌约4%，至55.71美元</p><p>** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (<span>link</span>) </p><p>** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节</p><p>** 多伦多道明 Cowen 分析师泰勒·范·布伦（Tyler Van Buren）表示，这一进展“略显令人失望”，因为诺如病毒曾是除新冠、呼吸道合胞病毒（RSV）和流感之外，晚期传染病领域中前景较为明朗的机遇之一</p><p>** 他表示，这一挫折使该项目从潜在的2026年催化剂转向了更不确定的研发路径，同时也可能对更广泛的mRNA平台生产力讨论产生一定程度的负面影响</p><p>** 公司报告第二季度营收为1.45亿美元，超过分析师预估的1.03亿美元——数据由LSEG汇编</p><p>** 计入盘中波动，该股今年以来累计涨幅约为90% </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-08-01 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折</title></head><body><p><span>7月31日</span><span> - </span>** 疫苗制造商莫德纳（<a href=\"https://laohu8.com/S/MRNA\">Moderna</a>） <span>MRNA.O</span> 的股价下跌约4%，至55.71美元</p><p>** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (<span>link</span>) </p><p>** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节</p><p>** 多伦多道明 Cowen 分析师泰勒·范·布伦（Tyler Van Buren）表示，这一进展“略显令人失望”，因为诺如病毒曾是除新冠、呼吸道合胞病毒（RSV）和流感之外，晚期传染病领域中前景较为明朗的机遇之一</p><p>** 他表示，这一挫折使该项目从潜在的2026年催化剂转向了更不确定的研发路径，同时也可能对更广泛的mRNA平台生产力讨论产生一定程度的负面影响</p><p>** 公司报告第二季度营收为1.45亿美元，超过分析师预估的1.03亿美元——数据由LSEG汇编</p><p>** 计入盘中波动，该股今年以来累计涨幅约为90% </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X26E:1","article_id":"2656956093","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656956093","pubTimestamp":1785522454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折7月31日-** 疫苗制造商莫德纳（Moderna）MRNA.O的股价下跌约4%，至55.71美元** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (link)** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节** 多伦多道明 Cowen 分析师泰勒","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","WDNA":"WisdomTree BioRevolution Fund","BK4568":"美国抗疫概念","BK4501":"段永平概念","BK4585":"ETF&股票定投概念","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4139":"生物科技","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","IDNA":"iShares Genomics Immunology and Healthcare ETF","BK4532":"文艺复兴科技持仓","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4551":"寇图资本持仓","MRNY":"MRNA期权收益策略ETF-YieldMax","GNOM":"Global X Genomics & Biotechnology ETF"},"translate_title":"Moderna Stock Falls as Norovirus Vaccine Trial Sets Setback","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"WDNA":0.6,"MRNY":0.6,"GNOM":0.6,"LGHT":0.6,"IDNA":0.6,"MRNX":0.6},"content_text":"BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折7月31日 - ** 疫苗制造商莫德纳（Moderna） MRNA.O 的股价下跌约4%，至55.71美元** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (link) ** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节** 多伦多道明 Cowen 分析师泰勒·范·布伦（Tyler Van Buren）表示，这一进展“略显令人失望”，因为诺如病毒曾是除新冠、呼吸道合胞病毒（RSV）和流感之外，晚期传染病领域中前景较为明朗的机遇之一** 他表示，这一挫折使该项目从潜在的2026年催化剂转向了更不确定的研发路径，同时也可能对更广泛的mRNA平台生产力讨论产生一定程度的负面影响** 公司报告第二季度营收为1.45亿美元，超过分析师预估的1.03亿美元——数据由LSEG汇编** 计入盘中波动，该股今年以来累计涨幅约为90%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656956093","isCrawlerRequest":true}